Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Wild Type”

113 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 113 results

Testing effectiveness (Phase 2)UnknownNCT02296203
What this trial is testing

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 27
Not applicableEnded earlyNCT01074333
What this trial is testing

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Who this might be right for
Colorectal Neoplasm
Merck KGaA, Darmstadt, Germany 146
Not applicableActive Not RecruitingNCT02394834
What this trial is testing

An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Who this might be right for
Colorectal Cancer
Takeda 757
Testing effectiveness (Phase 2)UnknownNCT04189055
What this trial is testing

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.

Who this might be right for
Cancer Colorectal
Hôpital Franco-Britannique-Fondation Cognacq-Jay 72
Testing effectiveness (Phase 2)UnknownNCT01322178
What this trial is testing

Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients

Who this might be right for
Colorectal CancerLiver Metastases
Fudan University 90
Early research (Phase 1)Study completedNCT01294826
What this trial is testing

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Who this might be right for
Recurrent Colon CancerRecurrent Rectal CancerStage IV Colon Cancer+3 more
Swedish Medical Center 20
Large-scale testing (Phase 3)Study completedNCT01001377
What this trial is testing

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Amgen 1,010
Testing effectiveness (Phase 2)Study completedNCT02404935
What this trial is testing

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

Who this might be right for
Metastatic Colorectal Cancer
UNICANCER 139
Early research (Phase 1)Active Not RecruitingNCT01787500
What this trial is testing

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Who this might be right for
BRAF NP_004324.2:p.V600XKRAS wt AlleleMetastatic Malignant Solid Neoplasm+4 more
M.D. Anderson Cancer Center 33
Testing effectiveness (Phase 2)Study completedNCT03446157
What this trial is testing

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Who this might be right for
Cancer of the ColonColon CancerColon Neoplasms+2 more
UNC Lineberger Comprehensive Cancer Center 24
Testing effectiveness (Phase 2)Study completedNCT00553254
What this trial is testing

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Who this might be right for
Carcinoma, Non Small Cell Lung
Pfizer 55
Testing effectiveness (Phase 2)Study completedNCT01443377
What this trial is testing

Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer

Who this might be right for
Rectal Cancer
National Center for Tumor Diseases, Heidelberg 48
Testing effectiveness (Phase 2)Study completedNCT01226719
What this trial is testing

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Who this might be right for
Colorectal Cancer
SCRI Development Innovations, LLC 15
Not applicableEnded earlyNCT01134666
What this trial is testing

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Who this might be right for
Colorectal Neoplasms
Merck KGaA, Darmstadt, Germany 165
Not applicableStudy completedNCT03914170
What this trial is testing

Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle 70
Not applicableStudy completedNCT02089737
What this trial is testing

Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

Who this might be right for
Advanced or Recurrent Colorectal Cancer
Takeda 3,091
Testing effectiveness (Phase 2)Study completedNCT01075048
What this trial is testing

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Daiichi Sankyo 131
Testing effectiveness (Phase 2)Study completedNCT01202409
What this trial is testing

CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Who this might be right for
Gastrointestinal Cancer
M.D. Anderson Cancer Center 19
Not applicableStudy completedNCT02322736
What this trial is testing

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR

Who this might be right for
Metastatic Colorectal Cancer
Amgen 218
Testing effectiveness (Phase 2)Study completedNCT03442569
What this trial is testing

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Who this might be right for
Colon Cancer
UNC Lineberger Comprehensive Cancer Center 56
Load More Results